• Publications
  • Influence
Chlorambucil plus rituximab with or without maintenance rituximab as first‐line treatment for elderly chronic lymphocytic leukemia patients
In a phase II trial, we evaluated chlorambucil and rituximab (CLB‐R) as first‐line induction treatment with or without R as maintenance for elderly chronic lymphocytic leukemia (CLL) patients.Expand
  • 98
  • 5
  • PDF
Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in the Western world, whereas in Asia the incidence is about 10 times lower. The basis for this ethnic and geographic variationExpand
  • 23
  • 3
  • PDF
IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL)
B-prolymphocytic leukemia (B-PLL) is a rare disease with poor prognosis. To further characterize the biological features of this disease, we analyzed immunoglobulin heavy chain (IgVH) mutations,Expand
  • 41
  • 1
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia
BIRC3 is a recurrently mutated gene in chronic lymphocytic leukemia (CLL) but the functional implications of BIRC3 mutations are largely unexplored. Furthermore, little is known about the prognosticExpand
  • 16
  • 1
  • PDF
Identification of molecular and functional patterns of p53 alterations in chronic lymphocytic leukemia patients in different phases of the disease
We analyzed TP53 mutations in 483 chronic lymphocytic leukemia patients at different phases of the disease and found a higher incidence of mutations at the later phases and a distinctive mutationExpand
  • 15
  • 1
  • PDF
B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures
B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures
  • 35
Disruption of BIRC 3 associates with fludarabine chemorefractoriness in TP 53 wild-type chronic lymphocytic leukemia
*Davide Rossi,1 *Marco Fangazio,1 *Silvia Rasi,1 Tiziana Vaisitti,2 Sara Monti,1 Stefania Cresta,1 Sabina Chiaretti,3 Ilaria Del Giudice,3 Giulia Fabbri,4 Alessio Bruscaggin,1 Valeria Spina,1 ClaraExpand
  • 20
Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B‐cell receptor structure, function, and patients' prognosis
Chronic lymphocytic leukemia (CLL) with stereotyped B‐cell receptor (BCR) belonging to subset #1 (IGHV1‐5‐7/IGKV1‐39) display a poor outcome. To characterize their genetic and genomic features andExpand
  • 17
Bendamustine in the Treatment of Chronic Lymphocytic Leukemia - Consistent Superiority Over Chlorambucil in Elderly Patients and Across Clinically Defined Risk Groups
Abstract 2367 Poster Board II-344 Introduction: Bendamustine is a purine analog/alkylator hybrid agent with a unique mechanism of action, which has shown good clinical efficacy and acceptableExpand
  • 14
Histopathological and molecular features of persistent
Summary Five cases of persistent polyclonal B-cell lymphocytosis (PPBL) with progressive splenomegaly are reported; three were splenectomized. BCL2/ IGH rearrangements were found in three cases;Expand
  • 2